177 related articles for article (PubMed ID: 20573851)
21. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Hill KL; Lipson AC; Sheehan JM
J Neurosurg; 2009 Sep; 111(3):497-503. PubMed ID: 19199506
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
23. Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Cicek D; Kandi B; Dagli FA; Karaoglu A; Haligur BD
Clin Drug Investig; 2008; 28(12):803-7. PubMed ID: 18991474
[TBL] [Abstract][Full Text] [Related]
24. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
25. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Berchem G; Dewilde S; Mahassen P
Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
[TBL] [Abstract][Full Text] [Related]
26. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
[TBL] [Abstract][Full Text] [Related]
27. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
[TBL] [Abstract][Full Text] [Related]
28. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Overkleeft EN; Goldschmeding R; van Reekum F; Voest EE; Verheul HM
Ann Oncol; 2010 Jan; 21(1):184-5. PubMed ID: 19889617
[No Abstract] [Full Text] [Related]
29. Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Galán Brotons A; Borrás-Blasco J; Rosique-Robles JD; Vicent Verge JM; Casterá ME
Clin Transl Oncol; 2008 Dec; 10(12):844-6. PubMed ID: 19068457
[TBL] [Abstract][Full Text] [Related]
30. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Tamaskar I; Bukowski R; Elson P; Ioachimescu AG; Wood L; Dreicer R; Mekhail T; Garcia J; Rini BI
Ann Oncol; 2008 Feb; 19(2):265-8. PubMed ID: 17962201
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Lekili M; Muezzinoglu T; Nese N; Temeltas G
J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
[TBL] [Abstract][Full Text] [Related]
32. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Raspollini MR
Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
[No Abstract] [Full Text] [Related]
33. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
34. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib TARGET trial results in Spanish patients.
Bellmunt J; González-Larriba JL; Climent MA; López-Vivanco G; Urruticoechea L; Albanell J
Clin Transl Oncol; 2007 Oct; 9(10):671-3. PubMed ID: 17974528
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
37. Chloracne-like drug eruption associated with sorafenib.
Pickert A; Hughes M; Wells M
J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
[TBL] [Abstract][Full Text] [Related]
38. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Scandurra G; Aiello RA; Alì M; Taibi E; Sanò MV; Todaro FM; La Rocca R; Licciardello P; Caruso M
Future Oncol; 2012 May; 8(5):609-15. PubMed ID: 22646774
[TBL] [Abstract][Full Text] [Related]
39. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW
Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828
[TBL] [Abstract][Full Text] [Related]
40. [Sorafenib-induced multiple eruptive keratoacanthomas].
Jantzem H; Dupre-Goetghebeur D; Spindler P; Merrer J
Ann Dermatol Venereol; 2009 Dec; 136(12):894-7. PubMed ID: 20004316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]